Diabetes
2
Companies
11
Drug Programs
10
Phase 3
0
Upcoming PDUFAs
Novo Nordisk A/S
biphasic human insulin
Novo Nordisk A/S
biphasic insulin aspart
Novo Nordisk A/S
biphasic human insulin
Novo Nordisk A/S
insulin NPH
Novo Nordisk A/S
metformin
Novo Nordisk A/S
human insulin
Novo Nordisk A/S
sitagliptin
Novo Nordisk A/S
rosiglitazone
Novo Nordisk A/S
biphasic insulin aspart 50
Novo Nordisk A/S
DPP-4 inhibitor
Novo Nordisk A/S
insulin 338 (GIPET I)
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| NOVO-B.CO Novo Nordisk A/S | biphasic human insulin | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | biphasic insulin aspart | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | biphasic human insulin | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | insulin NPH | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | metformin | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | human insulin | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | sitagliptin | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | rosiglitazone | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | biphasic insulin aspart 50 | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | DPP-4 inhibitor | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | insulin 338 (GIPET I) | Phase 2 | — | — | — |
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.